Zepbound coverage is conditional
Medicare generally won’t cover Zepbound (tirzepatide) for obesity alone, but the program can pay for it if a patient has obstructive sleep apnea — so a sleep‑apnea diagnosis can open a coverage pathway. (Budget Seniors and related coverage explain that Medicare’s Part D rules exclude obesity‑only coverage but allow Zepbound for obstructive sleep apnea) (budgetseniors.com).
A drug that Medicare usually won’t pay for can suddenly become coverable if the prescription is tied to a different diagnosis on the label. That is the loophole-like reality behind Zepbound, the Eli Lilly drug better known for weight loss. (fda.gov) Medicare Part D has long excluded drugs “when used for” weight loss, which is why obesity alone usually does not unlock coverage for Zepbound. The key phrase is “when used for,” because the same drug can be covered if it is being used for a different Food and Drug Administration-approved condition. (cms.gov) That second condition arrived on December 20, 2024, when the Food and Drug Administration approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. The agency called it the first medication approved for that sleep disorder. (fda.gov) Obstructive sleep apnea is the form where the upper airway repeatedly collapses during sleep, like a soft straw pinching shut over and over through the night. The Food and Drug Administration approval applies only to adults who have both obesity and moderate to severe disease. (fda.gov) Once that approval existed, Medicare drug plans had a path to treat Zepbound as a Part D drug for sleep apnea instead of a weight-loss drug. In January 2025, the Centers for Medicare & Medicaid Services confirmed that Medicare plans could cover Zepbound for obstructive sleep apnea. (cnbc.com) That does not mean every person with extra weight can get it through Medicare. A patient still needs the sleep apnea diagnosis, and plans can still use tools like prior authorization to check whether the prescription matches the approved use. (sleepfoundation.org) The policy line got even sharper in April 2025. The Centers for Medicare & Medicaid Services issued its final rule for 2026 on April 4, 2025, and did not finalize the earlier proposal that would have broadened Medicare Part D coverage for anti-obesity drugs. (cms.gov, healio.com) So the practical map is narrow. If Zepbound is prescribed for obesity by itself, Medicare generally still says no, but if it is prescribed for obstructive sleep apnea in a patient who fits the approved label, Medicare Part D may say yes. (aspe.hhs.gov, fda.gov) That is why a sleep study now matters financially as much as medically for some older patients. The diagnosis does not change the drug, but it changes which rulebook Medicare uses when deciding whether the bill gets paid. (healthline.com, cms.gov)
